Henrik Grönberg
Professor, head of department
Present position and assignments:
Professor in cancer epidemiology, KI
Head of KI Biobank Council
Head of Steering Committee for the Centre for Violence Prevention (CVP)
Member of the Steering Committee for biobank KI/SLL
Member of Steering group for SFO Cancer (StratCan)
KIs representative in the National Reference Committee for Science for Life Lab (NRK)
Education
1987 M.D. Medicine, Umeå University, Sweden, 1994 specialist in oncology
1995 Ph.D. Oncology, Umeå University, Sweden
1996-1997 Post Doc Urology, Johns Hopkins University, USA
2002 professor of oncology, Umeå University, Sweden
Summary of ongoing research with links to project pages
My research is focused on identifying new markers both for the risk of getting prostate cancer and for the prognosis of prostate cancer once diagnosed. There are two main tracks in my research today:
1. Identification and clinical implementation of new biomarkers in prostate cancer.
For 15 years, my research has been focused on identifying inherited genetic variations (SNPs) that are associated with prostate cancer. Our research group has together with an international consortium, PRACTICAL, identified a majority of the currently known 70 SNPs that are associated with prostate cancer. Moreover, we have a program to identify new biomarkers (proteins) in the blood. In these studies we try to both find markers that identify prostate cancer and more importantly, find those associated with the aggressive form of prostate cancer.
During 2010-2012, we included about 26,000 men in the STHLM2-study (see below) where we systematically validated both old and new biomarkers. As a logical continuation of this project, in the autumn of 2012 we started a large randomized clinical trial of diagnostics, STHLM3 (see below) where we compare PSA with a combination panel based on other biomarkers (both genetic and proteins). We will invite all men in Stockholm and Gotland aged 50-69 years during 2012-2014.
2. Characterization of prostate tumors using large-scale sequencing
In this project (ICAP, Integrated Analysis of Prostate Cancer) we analyze prostate tumors using "next generation sequencing". We work closely with the pathology department at Karolinska Hospital where there is a biobank with at least 1,000 fresh frozen prostate tumors collected since 2001. Today, we have analyzed 50 tumors with whole genome sequencing and RNA sequencing. We have identified a number of genes in which somatic mutations and variation that are significantly overrepresented and some are also associated with bad prognosis. We now continue with the analysis of approximately 250 additional tumors. In parallel, we evaluate the possibility of using circulating tumor DNA in plasma as an individualized biomarker for prostate cancer. These analyzes are done at the Science for Life Laboratory in Stockholm. In the future, we see an opportunity to use large-scale genomic analysis to tailor therapy for prostate cancer.
Henrik Grönberg's research was judged by the ERA-evaluation in 2011 as "outstanding".
Research projects
- STHLM-2
- STHLM-1
- Linneus centre CRisP for prevention of breast and prostate cancer
- Studies of families with hereditary prostate cancer
- Cancer of the Prostate in Sweden (CAPS)
- Lifestyle and genetic factors in the progression of prostate cancer
- Identification of independent genetic markers and lifestyle factors for prostate cancer progression and death
- Identification of independent genetic markers and lifestyle factors for prostate cancer progression and death
Publications
Google Scholar [Jan 2013]
| All | Since 2008 | |
|---|---|---|
| Quotations | 9565 | 5570 |
| h-index | 44 | 33 |
| i10-index | 131 | 113 |
Identification of a new prostate cancer susceptibility locus on chromosome 8q24.
Nat Genet 2009;41:1055-7.
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
Proc Natl Acad Sci U S A 2010;107:2136-40.
Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins.
Eur Urol 2012, in press.
Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003-2011.
Eur Urol 2012, in press.
Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003-2011.
Eur Urol 2012, in press.
Current research grants (as PI)
Swedish Research Council
Genomics of prostate cancer: From gene identification to clinical applications
Total sum: 5 200 000 SEK (2013-2016)
************************************************************
Swedish Cancer Society
Genomics of prostate cancer: From gene identification to clinical applications
Total sum: 6 000 000 SEK (2013-2015)
************************************************************
Stockholm County Council, ALF-grant
Validation of the importance of genetic markers as a complement to PSA in prostate. A biobank for research on prostate cancer.
Total sum: 3 000 000 SEK (2011-2013)
************************************************************
Astra Zeneca/Karolinska Institutet
Circulating tumor DNA as a personlised biomarker for treatment predication and disease monitoring in prostate and breast cancer.
Total sum: 9 200 000 SEK (2013-2016)
************************************************************
Stockholm County Council, grant
The STHLM-3 study: Prostate cancer diagnostic randomized trial.
Total sum: 40 000 000 SEK (2012-2014)
************************************************************
Stockholm County Council, grant
The STHLM-3 study: Prostate cancer diagnostic randomized trial.
Total sum: 40 000 000 SEK (2012-2014)
************************************************************
